Showing results (421-430 of 500) with videos related to

Sort By:
Pageof 50
The Lancet. Oncology|October 30, 2025
Artificial Intelligence for Response Assessment in Pediatric Neuro-Oncology (AI-RAPNO), part 1: review of the current state of the artBenjamin H Kann, Arastoo Vossough, Sarah C Brüningk, et al.
Neuro-Oncology|January 29, 2014
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02Patrick Y Wen, Susan M Chang, Kathleen R Lamborn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2026
A genomically-tailored multi-agent precision medicine clinical trial for adults with recurrent glioblastomaJiaying Chen, Nancy Ann Oberheim Bush, Jennifer A Grabowsky, et al.
AJNR. American Journal of Neuroradiology|December 8, 2025
Focused Ultrasound in Brain Tumors: Mechanisms, Imaging Guidance, and Emerging Clinical ApplicationsAli Nabavizadeh, Kazim Narsinh, Timothy J Kaufmann, et al.
Neuro-Oncology Advances|December 23, 2020
Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adultsJessica D Schulte, Robin A Buerki, Sarah Lapointe, et al.
The Lancet. Oncology|November 3, 2023
A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma: joint recommendations from four RANO groupsPhilipp Karschnia, Marion Smits, Guido Reifenberger, et al.
Neuro-Oncology|April 6, 2021
Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experienceEudocia Q Lee, Wendy Selig, Clair Meehan, et al.
Neuro-Oncology|April 6, 2021
Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomasYao Yu, Javier Villanueva-Meyer, Matthew R Grimmer, et al.
The Lancet. Oncology|October 30, 2025
Artificial Intelligence for Response Assessment in Pediatric Neuro-Oncology (AI-RAPNO), part 2: challenges, opportunities, and recommendations for clinical translationAnahita Fathi Kazerooni, Ariana M Familiar, Mariam Aboian, et al.
The Lancet. Oncology|January 6, 2018
Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working groupD Ross Camidge, Eudocia Q Lee, Nancy U Lin, et al.
Pageof 50